arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Longeveron Inc.

LGVN
$2.77 ▲ +0.32 (+13.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
30 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Longeveron Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $86.9M
Dividend Yield
Revenue Growth -9.2%
Op. Margin None
ROIC -46.9%
FCF / Share $-0.18
Trailing P/E
Price / Book 8.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$287.00K
↓ -9.2%
Net Income Profit after all expenses
$-6.07M
↓ -20.8%
Operating Margin Operating profit as % of sales
-117.2%
↓ -128.2%
FCF / Share Free cash flow per share
$-0.18
↓ -103947.2%
Long-Term Debt Long-term obligations
$143.00K
↓ -1.4%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -324.2% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.83x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters